FDA head urges probe of agency’s dealings with Biogen, maker of controversial new Alzheimer’s drug

The approval of Aduhelm set off a firestorm, with critics saying the medication doesn’t work and accusing the agency of getting too close to the company.

View original article
Contributor: Laurie McGinley